48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)

por Arastéh, K, Ward, A, Plettenberg, A, Livrozet, JM, Cordes, C, Winston, A, Wang, E, Quinson, A
Publicado 2010

Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome

por Baudry, T, Boibieux, A, Gagnieu, MC, Cotte, L, Livrozet, JM, Miahles, P, Makhloufi, D, Chidiac, C, Peyramond, D, Ferry, T
Publicado 2010

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug

por Billaud, E, Lacombe, JM, Abgrall, A, Ghosn, J, Launay, O, Livrozet, JM, Meynard, JL, Pavie, J, Costagliola, D
Publicado 2010

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961)

por Eron, J, Livrozet, JM, Morlat, P, Lazzarin, A, Katlama, C, Hawkins, T, Fujiwara, T, Cuffe, R, Vavro, C, Santiago, J, Ait-Khaled, M, Min, S, Yeo, JM
Publicado 2010